摘要
目的观察小剂量枸橼酸托瑞米芬联合消乳散结胶囊治疗男性乳房肥大症的疗效。方法回顾性分析2015年1月至2017年6月接受治疗的100例男性乳房肥大症患者的临床资料,其中观察组50例,采用小剂量枸橼酸托瑞米芬联合消乳散结胶囊治疗,对照组50例,采用单用消乳散结胶囊治疗,比较两组的治疗效果、不良反应发生率及治疗前后两组患者雌二醇、睾酮、泌乳素水平变化。结果观察组的治疗总体有效率为95%,对照组患者的治疗总有效率为82%,观察组患者的总体有效率明显高于对照组(P<0.05);观察组不良反应发生率14%,对照组不良反应发生率26%,观察组低于对照组(P<0.05)。治疗后对照组雌二醇、睾酮水平低于治疗前(P<0.05),治疗后观察组睾酮水平低于治疗前(P<0.05);治疗后观察组雌二醇、泌乳素水平低于治疗后对照组(P<0.05)。结论小剂量枸橼酸托瑞米芬联合消乳散结胶囊治疗男性乳房肥大症有效缓解患者的临床症状,减少不良反应发生率,效果显著,值得在临床推广。
Objective To observe the curative effect of small doses of Torrimifen citrate joint Xiaoru Sanjie capsules in the treatment of male breast hypertrophy. Methods A retrospective analysis in January 2015 to June 2017 clinical data of 100 patients with male breast hypertrophy,the observation group of 50 cases, by using small dose of Torrimifen citrate joint Xiaoru Sanjie capsules treatment, the control group, 50 cases with alone Xiaoru Sanjie capsules treatment, compare the treatment effect of the two groups, the incidence of adverse reactions and two groups of patients before and after the treatment estradiol, testosterone, prolactin level changes. Results The total effective rate of treatment was 95% in the observation group, and the total effective rate of treatment was 82% in the control group. The total effective rate of patients in the observation group was significantly higher than that in the control group(P〈0.05). The adverse reaction rate was 14% in the observation group and 26% in the control group. The observation group was lower than the control group(P〈0.05). The control group after treatment estradiol, testosterone levels lower than before treatment(P〈0.05), testosterone levels after treatment group is lower than before treatment(P〈0.05). After treatment, the level of estradiol and prolactin was lower than that in the control group(P〈0.05). Conclusion Small dose of Torrimifen citrate joint Xiaoru Sanjie capsules in the treatment of male breast hypertrophy, therapeutic effect is remarkable, can effectively alleviate the patient's clinical symptoms, and lower incidence of adverse reactions, is worth popularizing in clinical.
作者
王苏
武文杰
王德年
郭盼盼
李韶山
周进学
WANG Su;WU Wen-jie;WANG De-nian(Department of Generalsurgery,the Third Affliated Hospital of Xinxiang Medical University,Xinxiang 453003,Henan Province,China)
出处
《罕少疾病杂志》
2018年第5期42-44,共3页
Journal of Rare and Uncommon Diseases
基金
国家自然科学基金资助项目(编号:U1304818)